Medtronic schedules Q1 FY26 earnings release for August 19

Geoff Martha   Chairman and CEO Medtronic plc
Geoff Martha Chairman and CEO - Medtronic plc
0Comments

Medtronic plc announced it will release its financial results for the first quarter of fiscal year 2026 on Tuesday, August 19, 2025. The quarter ended on July 25, 2025.

The company stated that a news release with summary financial information will be available at approximately 5:45 a.m. Central Daylight Time (CDT) on its website at https://news.medtronic.com. A video webcast to discuss the results is scheduled to begin at 7:00 a.m. CDT and can be accessed at https://investorrelations.medtronic.com. Medtronic noted that within 24 hours after the webcast, both a replay and transcript of the prepared remarks will be accessible by clicking on the Events link at https://investorrelations.medtronic.com.

Medtronic also outlined its schedule for future earnings reports in fiscal year 2026. The company plans to announce second, third, and fourth quarter results on November 18, 2025; February 17, 2026; and May 20, 2026, respectively. Additional details about these events will be provided closer to each date.

“Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary,” according to information provided by Medtronic.

The company reminded investors that any forward-looking statements may involve risks or uncertainties as described in its periodic filings with the Securities and Exchange Commission.

For further information about Medtronic’s business or upcoming announcements visit www.Medtronic.com or follow their LinkedIn page.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.